More men at risk for prostate cancer as a result of less regular screening
the ONA take:
A recent research study examined the potential benefits and potential downsides to the US Preventive Services Task Force (USPSTF) recommendation against regular prostate-specific antigen (PSA) screening for prostate cancer.
Researchers, led by Daniel A. Barocas, MD, MPH, of the Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, examined the number and distribution of new prostate cancer diagnoses in the United States.
Incident cancers diagnosed from January 2010 through December 2012 were included. The number of new prostate cancer cases diagnosed before and after the USPSTF recommendation were compared against a similar record of colon cancer findings.
The investigators found a drop in the number of prostate cancer diagnoses, a greater than 12% decline, following the USPSTF's PSA screening recommendation.
Prostate cancer diagnoses at all risk levels fell, though new diagnoses of nonlocalized disease did not change. Monthly colon cancer diagnoses remained steady before and after the USPSTF recommendation.
One year after the USPSTF recommendation, diagnoses of new low risk cancers dropped by nearly 38%, which does address the USPSTF intent to reduce overdiagnosis, but the researchers have concerns that the reduction in high- and immediate-risk disease diagnoses could lower chances for early detection and treatment.
pThe team feels that additional research into screening models to maximize early detection for higher risk cancers while keeping overdiagnosis and overtreatment numbers low would be beneficial.
Data from this study were published in The Journal of Urology.
A recent study examined the potential benefits and potential downsides to the USPSTF recommendation against regular PSA screening.
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- Specialized Interventions Reduce Aberrant Opioid Behaviors in Cancer Patients
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
- Overall Survival Increase for Melanoma Brain Metastases
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|